SAFETY DATA SHEET

Pembrolizumab Solid Formulation

Section 1: Identification

Product name : Pembrolizumab Solid Formulation

Manufacturer or supplier’s details
Company : MSD
Address : 33 Whakatiki Street - Private Bag 908
          Upper Hutt - New Zealand
Telephone : +1-908-740-4000
Emergency telephone number : +1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

Section 2: Hazard identification

GHS Classification
Reproductive toxicity : Category 1B
Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Immune system)

GHS label elements
Hazard pictograms : ☢️
Signal word : Danger
Hazard statements : H360D May damage the unborn child.
                   H372 Causes damage to organs (Immune system) through prolonged or repeated exposure if swallowed.
Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/
SAFETY DATA SHEET

Pembrolizumab Solid Formulation

Version 2.9  
Revision Date: 27.08.2021  
SDS Number: 525400-00011  
Date of last issue: 18.05.2021  
Date of first issue: 23.02.2016

attention.

Storage:  
P405 Store locked up.

Disposal:  
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chemical name</td>
</tr>
<tr>
<td></td>
<td>Sucrose</td>
</tr>
<tr>
<td></td>
<td>Pembrolizumab</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child.  
Causes damage to organs through prolonged or repeated exposure if swallowed.  
Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.
Section 5: Fire-fighting measures

- **Suitable extinguishing media**: Water spray
  - Alcohol-resistant foam
  - Carbon dioxide (CO2)
  - Dry chemical

- **Unsuitable extinguishing media**: None known.

- **Specific hazards during firefighting**: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

- **Hazardous combustion products**: Carbon oxides
  - Nitrogen oxides (NOx)

- **Specific extinguishing methods**: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
  - Use water spray to cool unopened containers.
  - Remove undamaged containers from fire area if it is safe to do so.
  - Evacuate area.

- **Special protective equipment for firefighters**: In the event of fire, wear self-contained breathing apparatus.
  - Use personal protective equipment.

Section 6: Accidental release measures

- **Personal precautions, protective equipment and emergency procedures**: Use personal protective equipment.
  - Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

- **Environmental precautions**: Avoid release to the environment.
  - Prevent further leakage or spillage if safe to do so.
  - Retain and dispose of contaminated wash water.
  - Local authorities should be advised if significant spillages cannot be contained.

- **Methods and materials for containment and cleaning up**: Sweep up or vacuum up spillage and collect in suitable container for disposal.
  - Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
  - Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
  - Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
  - Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

- **Technical measures**: Static electricity may accumulate and ignite suspended dust
causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucreose</td>
<td>57-50-1</td>
<td>WES-TWA</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>1374853-91-4</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

|                     | 75 µg/m³ (OEB 3) | Internal                     |

Engineering measures: Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust ventilation.
SAFETY DATA SHEET

Pembrolizumab Solid Formulation

Version 2.9  Revision Date: 27.08.2021  SDS Number: 525400-00011  Date of last issue: 18.05.2021  Date of first issue: 23.02.2016

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection

Material: Chemical-resistant gloves

Remarks: Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection: Wear the following personal protective equipment:
Safety goggles

Skin and body protection: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Section 9: Physical and chemical properties

Appearance: powder
Colour: white to off-white
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Section 10: Stability and reactivity

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
- May form explosive dust-air mixture during processing, handling or other means.
- Can react with strong oxidizing agents.

Conditions to avoid:
- Heat, flames and sparks.
- Avoid dust formation.

Incompatible materials:
- Oxidizing agents

Hazardous decomposition products:
- No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes:
- Inhalation
- Skin contact
- Ingestion
- Eye contact
Acute toxicity
Not classified based on available information.

Components:
Sucrose:
Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Chronic toxicity
Germ cell mutagenicity
Not classified based on available information.

Components:
Sucrose:
Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
May damage the unborn child.

Components:
Pembrolizumab:
Reproductive toxicity - Assessment : May damage the unborn child., Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Causes damage to organs (Immune system) through prolonged or repeated exposure if swallowed.
Components:

Pembrolizumab:
Target Organs: Immune system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Pembrolizumab:
Species: Monkey
NOAEL: 200 mg/kg
Application Route: Intravenous
Exposure time: 180 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 200 mg/kg
Application Route: Intravenous
Exposure time: 180 d
Remarks: No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Pembrolizumab:
Inhalation: Target Organs: Immune system
Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis
Remarks: Damage to fetus possible

Section 12: Ecological information

Ecotoxicity
No data available

Persistence and degradability
No data available

Bioaccumulative potential

Components:

Sucrose:
Partition coefficient: n-: Pow: < 1
octanol/water

**Mobility in soil**
No data available

**Other adverse effects**
No data available

### Section 13: Disposal considerations

**Disposal methods**
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### Section 14: Transport information

**International Regulations**

#### UNRTDG
- UN number: Not applicable
- Proper shipping name: Not applicable
- Class: Not applicable
- Subsidiary risk: Not applicable
- Packing group: Not applicable
- Labels: Not applicable

#### IATA-DGR
- UN/ID No.: Not applicable
- Proper shipping name: Not applicable
- Class: Not applicable
- Subsidiary risk: Not applicable
- Packing group: Not applicable
- Labels: Not applicable
- Packing instruction (cargo aircraft): Not applicable
- Packing instruction (passenger aircraft): Not applicable

#### IMDG-Code
- UN number: Not applicable
- Proper shipping name: Not applicable
- Class: Not applicable
- Subsidiary risk: Not applicable
- Packing group: Not applicable
- Labels: Not applicable
- EmS Code: Not applicable
- Marine pollutant: Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.

**National Regulations**

**NZS 5433**
- UN number: Not applicable
Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

Section 16: Other information

Further information

Date format : dd.mm.yyyy

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average
NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NZ / EN